Boston Scientific (NYSE: BSX) reported Q1 EPS of $0.47, $0.04 better than the analyst estimate of $0.43. Revenue for the quarter came in at $3.39 billion versus the consensus estimate of $3.16 billion.

GUIDANCE:

Boston Scientific sees Q2 2023 EPS of $0.48-$0.50, versus the consensus of $0.48.

Boston Scientific sees FY2023 EPS of $1.90-$1.96, versus the consensus of $1.91.

"The company now estimates net sales growth for the full year 2023, versus the prior year period, to be approximately 8.5 to 10.5 percent on a reported basis, and approximately 8 to 10 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales."

"The company estimates net sales growth for the second quarter of 2023, versus the prior year period, to be in a range of approximately 6.5 to 8.5 percent on a reported basis, and approximately 7 to 9 percent on an organic basis. Second quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. "

For earnings history and earnings-related data on Boston Scientific (BSX) click here.